VEGF Signal Complexity Confers Resistance to Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer

Abstract

Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) therapy is beneficial for epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)-resistant non-small cell lung cancer (NSCLC); however, the resistance mechanisms are not fully understood. In this study, we conducted a single-cell RNA-sequencing analysis of EGFR-TKI-resistant NSCLC patients grouped into ABCP responders and non-responders. VEGFA was overexpressed in ABCP responders, whereas VEGFC was upregulated in non-responders. VEGFA and VEGFC had exclusive distributions and interactions, suggesting their distinct roles. VEGFA facilitated the proliferation of responder tumor subcluster cells, whereas VEGFC secreted from non-responder tumor cells interacted with tumor microenvironment cells. VEGFC predominantly cooperated with drug resistance pathways such as fibroblast growth factor signaling and YAP-TAZ regulation, whereas VEGFA coordinated several oncogenic signaling pathways. VEGFC expression was the most significant prognostic marker (hazard ratio, 1.8 [95% confidence interval, 1.1–3.0], p = 0.015). Both VEGFA and VEGFC inhibition effectively suppressed tumor growth, suggesting that VEGF signaling complexity hampers the response to ABCP. In conclusion, combinatorial targeting of both ligands (VEGFA and VEGFC) or their receptors (VEGFR2 and KDR) may enhance the clinical benefit of ABCP in EGFR-TKI-resistant NSCLC patients.

Keywords

ABCP therapy response / combination immunotherapy / non-small cell lung cancer / single-cell transcriptome analysis / VEGF signaling

References

[1] M. A. Socinski, M. Nishio, R. M. Jotte, et al., “IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC,” Journal of Thoracic Oncology 16 (2021): 1909-1924.

[2] F. Wu, J. Fan, Y. He, et al., “Single-Cell Profiling of Tumor Heterogeneity and the Microenvironment in Advanced Non-Small Cell Lung Cancer,” Nature Communications 12, no. 1 (2021): 2540.

[3] Y. Yang, S. Li, Y. Wang, Y. Zhao, and Q. Li, “Protein Tyrosine Kinase Inhibitor Resistance in Malignant Tumors: Molecular Mechanisms and Future Perspective,” Signal Transduction and Targeted Therapy 7 (2022): 329.

[4] S. C. Joosten, L. Hamming, P. M. Soetekouw, et al., “Resistance to Sunitinib in Renal Cell Carcinoma: From Molecular Mechanisms to Predictive Markers and Future Perspectives,” Biochimica et Biophysica Acta-Reviews on Cancer 1855, no. 1 (2015): 1-16.

[5] I. Moya-Horno, S. Viteri, N. Karachaliou, and R. Rosell, “Combination of Immunotherapy With Targeted Therapies in Advanced Non-Small Cell Lung Cancer (NSCLC),” Therapeutic Advances in Medical Oncology 10, no. 1 (2018): 1758834017745012.

[6] X. Le, M. Nilsson, J. Goldman, et al., “Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC,” Journal of Thoracic Oncology 16, no. 2 (2021): 205-215.

[7] H. L. Goel, and A. M. Mercurio, “VEGF Targets the Tumour Cell,” Nature Reviews Cancer 13, no. 11 (2013): 871-882.

[8] F. Shaik, G. A. Cuthbert, S. Homer-Vanniasinkam, S. P. Muench, S. Ponnambalam, and M. A. Harrison, “Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy,” Biomolecules 10, no. 12 (2020): 1673.

[9] S. Guo, L. S. Colbert, M. Fuller, Y. Zhang, and R. R. Gonzalez-Perez, “Vascular Endothelial Growth Factor Receptor-2 in Breast Cancer,” Biochimica et Biophysica Acta-Reviews on Cancer 1806, no. 2 (2010): 108-121.

[10] M. Shibuya and L. Claesson-Welsh, “Signal Transduction by VEGF Receptors in Regulation of Angiogenesis and Lymphangiogenesis,” Experimental Cell Research 312, no. 4 (2006): 549-560.

[11] K. Masłowska, P. K. Halik, D. Tymecka, A. Misicka, and E. Gniazdowska, “The Role of VEGF Receptors as Molecular Targets in Nuclear Medicine for Cancer Diagnosis and Combination Therapy,” Cancers (Basel) 13, no. 5 (2021): 1072.

[12] S. Park, T. M. Kim, J.-Y. Han, et al., “Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR—or ALK -Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04),” Journal of Clinical Oncology 42, no. 5 (2023): 1241-1251.

[13] M. A. Socinski, R. M. Jotte, F. Cappuzzo, et al., “Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC,” New England Journal of Medicine 378, no. 22 (2018): 2288-2301.

[14] J. Feng, S. Chen, S. Li, et al., “The Association Between Monocytic Myeloid-Derived Suppressor Cells Levels and the Anti-Tumor Efficacy of Anti-PD-1 Therapy in NSCLC Patients,” Translational Oncology 13, no. 1 (2020): 100865.

[15] E. Martino, G. Misso, P. Pastina, et al., “Immune-Modulating Effects of Bevacizumab in Metastatic Non-Small-Cell Lung Cancer Patients,” Cell Death Discovery 2, no. 1 (2016): 2.

[16] L. Jenkins, U. Jungwirth, A. Avgustinova, et al., “Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade,” Cancer Research 82, no. 7 (2022): 2904-2917.

[17] Z. Fu, A. M. Mowday, J. B. Smaill, I. F. Hermans, and A. V. Patterson, “Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy,” Cells 10, no. 11 (2021): 10.

[18] A. Leonetti, S. Sharma, R. Minari, P. Perego, E. Giovannetti, and M. Tiseo, “Resistance Mechanisms to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer,” British Journal of Cancer 121, no. 5 (2019): 725-737.

[19] N. Yu, M. Hwang, Y. Lee, et al., “Patient-Derived Cell-Based Pharmacogenomic Assessment to Unveil Underlying Resistance Mechanisms and Novel Therapeutics for Advanced Lung Cancer,” Journal of Experimental & Clinical Cancer Research 42, no. 1 (2023): 37.

[20] H. J. Whitfield, J. Berthelet, S. Mangiola, et al., “Single-Cell RNA Sequencing Captures Patient-Level Heterogeneity and Associated Molecular Phenotypes in Breast Cancer Pleural Effusions,” Clinical and Translational Medicine 13, no. 1 (2023): e1356.

[21] E. A. Collisson, J. D. Campbell, A. N. Brooks, et al., “Comprehensive Molecular Profiling of Lung Adenocarcinoma: The Cancer Genome Atlas Research Network,” Nature 511, no. 7507 (2014): 543-550.

[22] N. Kim, H. K. Kim, K. Lee, et al., “Single-Cell RNA Sequencing Demonstrates the Molecular and Cellular Reprogramming of Metastatic Lung Adenocarcinoma,” Nature Communications 11, no. 1 (2020): 2285.

[23] Y. Kieffer, H. R. Hocine, G. Gentric, et al., “Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer,” Cancer Discovery 10, no. 10 (2020): 1330-1351.

[24] H. Hu, Z. Piotrowska, P. J. Hare, et al., “Three Subtypes of Lung Cancer Fibroblasts Define Distinct Therapeutic Paradigms,” Cancer Cell 39, no. 10 (2021): 1531-1547.e10.

[25] W. Li, F. Wu, S. Zhao, P. Shi, S. Wang, D. Cui, “Correlation Between PD-1/PD-L1 Expression and Polarization in Tumor-Associated Macrophages: A Key Player in Tumor Immunotherapy,” Cytokine & Growth Factor Reviews 67, no. 2 (2022): 49-57.

[26] M. Puchert, J. Obst, C. Koch, K. Zieger, and J. Engele, “CXCL11 Promotes Tumor Progression by the Biased Use of the Chemokine Receptors CXCR3 and CXCR7,” Cytokine 125, no. 1 (2020): 154809.

[27] A. Makkouk, C. Chester, and H. E. Kohrt, “Rationale for Anti-CD137 Cancer Immunotherapy,” European Journal of Cancer 54, no. 1 (2016): 112-119.

[28] S. Nishina and K. Hino, “CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma,” Cancers (Basel) 14, no. 3 (2022): 454.

[29] A. Maynard, C. E. McCoach, J. K. Rotow, et al., “Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing,” Cell 182, no. 6 (2020): 1232-1251.e22.

[30] F. Sanchez-Vega, M. Mina, J. Armenia, et al., “Oncogenic Signaling Pathways in the Cancer Genome Atlas,” Cell 173, no. 2 (2018): 321-337.e10.

[31] X. Mao, J. Xu, W. Wang, et al., “Crosstalk Between Cancer-Associated Fibroblasts and Immune Cells in the Tumor Microenvironment: New Findings and Future Perspectives,” Molecular Cancer 20, no. 1 (2021): 131.

[32] G. N. Naumov, M. B. Nilsson, T. Cascone, et al., “Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance,” Clinical Cancer Research 15, no. 7 (2009): 3484-3494.

[33] H. Li, K. Takayama, S. Wang, et al., “Addition of Bevacizumab Enhances Antitumor Activity of Erlotinib Against Non-Small Cell Lung Cancer Xenografts Depending on VEGF Expression,” Cancer Chemotheraphy and Pharmacology 74, no. 6 (2014): 1297-305.

[34] F. Koinis, P. Corn, N. Parikh, et al., “Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer,” Cancers (Basel) 12, no. 2 (2020): 244.

[35] M. De Zuani, H. Xue, J. S. Park, et al., “Single-Cell and Spatial Transcriptomics Analysis of Non-Small Cell Lung Cancer,” Nature Communications 15, no. 1 (2024): 4388.

[36] J. Hu, L. Zhang, H. Xia, et al., “Tumor Microenvironment Remodeling After Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer Revealed by Single-Cell RNA Sequencing,” Genome Medicine 15, no. 1 (2023): 14.

[37] Z. Liu, Z. Yang, J. Wu, et al., “A Single-Cell Atlas Reveals Immune Heterogeneity in Anti-PD-1-Treated Non-Small Cell Lung Cancer,” Cell 11, no. 7 (2025): 3081-3096. e19.

[38] L. Yang, Y. T. He, S. Dong, et al., “Single-Cell Transcriptome Analysis Revealed a Suppressive Tumor Immune Microenvironment in EGFR Mutant Lung Adenocarcinoma,” Journal for ImmunoTherapy of Cancer 10, no. 1 (2022): e003534.

[39] M. Murakami, L. T. Nguyen, K. Hatanaka, et al., “FGF-Dependent Regulation of VEGF Receptor 2 Expression in Mice,” Journal of Clinical Investigation 121, no. 6 (2011): 2668-2678.

[40] B. Cha, Y. C. Ho, X. Geng, et al., “YAP and TAZ Maintain PROX1 Expression in the Developing Lymphatic and Lymphovenous Valves in Response to VEGF-C Signaling,” Development (Cambridge, England) 147, no. 13 (2020): dev195453.

[41] E. Ogawa, K. Takenaka, K. Yanagihara, et al., “Clinical Significance of VEGF-C Status in Tumour Cells and Stromal Macrophages in Non-Small Cell Lung Cancer Patients,” British Journal of Cancer 91, no. 4 (2004): 498-503.

[42] J. M. L. Ebos, C. R. Lee, W. Cruz-Munoz, G. A. Bjarnason, J. G. Christensen, and R. S. Kerbel, “Accelerated Metastasis After Short-Term Treatment With a Potent Inhibitor of Tumor Angiogenesis,” Cancer Cell 15, no. 3 (2009): 232-239.

[43] S. Loges, T. Schmidt, and P. Carmeliet, “Mechanisms of Resistance to Anti-Angiogenic Therapy and Development of Third-Generation Anti-Angiogenic Drug Candidates,” Genes & Cancer 1, no. 1 (2010): 12-25.

[44] R. Pedrosa, D. A. Mustafa, R. Soffietti, and J. M. Kros, “Breast Cancer Brain Metastasis: Molecular Mechanisms and Directions for Treatment,” Neuro-oncology 20, no. 10 (2018): 1439-1449.

[45] C. Zhu, Y. Wei, and X. Wei, “AXL Receptor Tyrosine Kinase as a Promising Anti-Cancer Approach: Functions, Molecular Mechanisms and Clinical Applications,” Molecular Cancer 18, no. 1 (2019): 153.

[46] A. Beenken and M. Mohammadi, “The FGF Family: Biology, Pathophysiology and Therapy,” Nat Rev Drug Discovery 8, no. 2 (2009): 235-253.

[47] T. Stuart, A. Butler, P. Hoffman, et al., “Comprehensive Integration of Single-Cell Data,” Cell 177, no. 6 (2019): 1888-1902. e21.

[48] I. Korsunsky, N. Millard, J. Fan, et al., “Fast, Sensitive and Accurate Integration of Single-Cell Data With Harmony,” Nature Methods 16, no. 12 (2019): 1289-1296.

[49] X. Qiu, A. Hill, J. Packer, D. Lin, Y. A. Ma, and C. Trapnell, “Single-Cell mRNA Quantification and Differential Analysis With Census,” Nature Methods 14, no. 5 (2017): 309-315.

[50] T. Wu, E. Hu, S. Xu, et al., “clusterProfiler 4.0: A Universal Enrichment Tool for Interpreting Omics Data,” Innovation 2, no. 1 (2021): 100141.

[51] A. Liberzon, C. Birger, H. Thorvaldsdóttir, M. Ghandi, J. P. Mesirov, and P. Tamayo, “The Molecular Signatures Database Hallmark Gene Set Collection,” Cell Systems 1, no. 6 (2015): 417-425.

[52] B. Jassal, L. Matthews, G. Viteri, et al., “The Reactome Pathway Knowledgebase,” Nucleic Acids Research 48, no. D1 (2020): D498-D503.

[53] M. Kanehisa, Y. Sato, M. Kawashima, M. Furumichi, and M. Tanabe, “KEGG as a Reference Resource for Gene and Protein Annotation,” Nucleic Acids Research 44, no. D1 (2016): D457-D462.

[54] M. Martens, A. Ammar, A. Riutta, et al., “WikiPathways: Connecting Communities,” Nucleic Acids Research 49, no. D1 (2021): D613-D621.

[55] A. P. Patel, I. Tirosh, J. J. Trombetta, et al., “Single-cell RNA-seq Highlights Intratumoral Heterogeneity in Primary Glioblastoma,” Science 344, no. 6186 (2014): 1396-1401.

[56] L. Garcia-Alonso, V. Lorenzi, C. I. Mazzeo, J. P. Alves-Lopes, K. Roberts, and C. Sancho-Serra, “Single-Cell Roadmap of human Gonadal Development,” Nature 607, no. 7917 (2022): 540-547.

[57] P. Shannon, A. Markiel, O. Ozier, et al., “Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks,” Genome Research 13, no. 11 (2003): 2498-2504.

[58] S. Jin, C. F. Guerrero-Juarez, L. Zhang, et al., “Inference and Analysis of Cell-Cell Communication Using CellChat,” Nature Communications 12, no. 1 (2021): 1088.

[59] A. Dobin, C. A. Davis, F. Schlesinger, et al., “STAR: Ultrafast Universal RNA-seq Aligner,” Bioinformatics 29, no. 1 (2013): 15-21.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.